Financial Data and Key Metrics Changes - Revenue for Q2 2025 was approximately $13.2 million, down from approximately $17 million in the same period last year, representing a decline of about 22% [7] - Year-to-date revenue was approximately $27.8 million compared to approximately $34.5 million for the same period last year, indicating a decrease of about 19% [7] - Gross profits from the healthcare segment decreased to approximately 20% in 2025 from 35% in 2024, primarily due to decreased prescription volume and changes in 340B revenue [10] - Gross profits from the e-commerce segment decreased to approximately 26% in 2025 from 32% in 2024, attributed to new airtime costs and temporary rate reductions for some customers [10] - Cash position at the end of Q2 was approximately $16.6 million [11] Business Line Data and Key Metrics Changes - Healthcare operations revenue declined due to decreased pharmacy prescription volume and changes in provider relationships [8] - E-commerce operations experienced an increase in revenue driven by growth in recurring airtime revenue and hardware sales [9] Market Data and Key Metrics Changes - E-commerce sales in China showed steady progress, limited by inventory import capabilities [4] - The tariff situation in the U.S. remains volatile, affecting operations in Florida [4] Company Strategy and Development Direction - The company is focused on refining healthcare operations, including personnel changes and improving operational efficiency [13] - New hires include pharmacy operations managers to enhance long-term growth and strategic planning [14] - The company is pursuing specialty pharmacy accreditation to access new revenue sources [15] Management Comments on Operating Environment and Future Outlook - Management acknowledges challenges in healthcare operations but sees potential for growth through cost reductions and operational efficiencies [5] - The company is committed to transparency and proactive steps to address challenges and invest for long-term success [16] Other Important Information - The company has not yet repurchased any shares under its repurchase program but plans to be active in the coming quarter [17] - The company is closely monitoring compliance with NASDAQ requirements and is prepared to utilize the grace period if necessary [18] Q&A Session Summary Question: What is the status of the buyback? - The company has not repurchased any shares yet but expects to be active in the coming quarter while being prudent with cash deployment [17] Question: What is the plan to regain compliance with NASDAQ? - The company is monitoring the situation and believes that executing strategic developments will be central to regaining compliance [18] Question: Should the company consider closing its business in China? - The company acknowledges tariff challenges but sees potential in the OpCo products and plans to launch animal health products in China [19]